Get the Stockscreener App
4.685
12.55%
0.515
Savara Inc stock is traded at $4.685, with a volume of 1.77M.
It is up +12.55% in the last 24 hours and up +30.01% over the past month.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
See More
Previous Close:
$4.17
Open:
$4.2
24h Volume:
1.77M
Relative Volume:
1.16
Market Cap:
$848.46M
Revenue:
-
Net Income/Loss:
$-54.70M
P/E Ratio:
-14.20
EPS:
-0.33
Net Cash Flow:
$-51.36M
1W Performance:
+13.92%
1M Performance:
+30.01%
6M Performance:
+49.95%
1Y Performance:
+59.64%
1-Day Range:
$4.17
$4.76
1-Week Range:
$4.03
$4.76
52-Week Range:
$1.89
$4.76
Savara Inc Stock (SVRA) Company Profile
Name
Savara Inc
Sector
Industry
Phone
51285113796
Address
6836 BEE CAVE ROAD, AUSTIN, TX
Compare SVRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SVRA
Savara Inc
|
4.69 | 848.46M | 0 | -54.70M | -51.36M | -0.33 |
|
ARGX
Argen X Se Adr
|
922.57 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
202.03 | 43.00B | 447.02M | -1.18B | -906.14M | -6.1812 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.51 | 110.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
ONC
Beone Medicines Ltd Adr
|
356.57 | 40.27B | 4.98B | 69.59M | 525.67M | 0.5197 |
|
REGN
Regeneron Pharmaceuticals Inc
|
705.74 | 76.23B | 14.25B | 4.58B | 3.88B | 41.77 |
Savara Inc Stock (SVRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Aug-15-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-29-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-20-24 | Initiated | Wells Fargo | Overweight |
| Nov-13-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-15-24 | Initiated | JMP Securities | Mkt Outperform |
| Nov-07-23 | Initiated | Guggenheim | Buy |
| May-16-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-31-23 | Downgrade | Jefferies | Buy → Hold |
| Mar-16-21 | Initiated | Piper Sandler | Overweight |
| Mar-15-21 | Initiated | Oppenheimer | Outperform |
| Jun-13-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-13-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-13-19 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Aug-13-18 | Resumed | ROTH Capital | Neutral |
| Jan-03-18 | Initiated | Ladenburg Thalmann | Buy |
| Sep-27-17 | Resumed | ROTH Capital | Buy |
| Sep-22-17 | Initiated | Jefferies | Buy |
| Sep-11-17 | Initiated | JMP Securities | Mkt Outperform |
View All
Savara Inc Stock (SVRA) Latest News
Savara Inc stock hits 52-week high at 4.51 USD By Investing.com - Investing.com South Africa
How Savara Inc. stock compares to industry benchmarksTrade Performance Summary & Free Real-Time Market Sentiment Alerts - newser.com
Savara Inc. stock momentum explainedQuarterly Portfolio Summary & Community Verified Watchlist Alerts - newser.com
Is Savara Inc. stock trading at a premium valuation2025 Stock Rankings & Safe Entry Trade Reports - newser.com
Short interest data insights for Savara Inc.2025 Geopolitical Influence & Weekly High Momentum Picks - newser.com
Savara Inc. $SVRA Shares Sold by Connor Clark & Lunn Investment Management Ltd. - MarketBeat
Multi asset correlation models including Savara Inc.Earnings Risk Summary & Weekly Return Optimization Plans - newser.com
Will Savara Inc. (YB4P) stock boost dividends furtherWeekly Risk Summary & Long-Term Capital Growth Ideas - newser.com
Will Savara Inc. stock continue dividend increases2025 Top Gainers & High Win Rate Trade Tips - newser.com
HC Wainwright Has Positive Outlook of Savara FY2029 Earnings - MarketBeat
Savara Inc. Reports Q3 2025 Financial Results - TipRanks
Lifesci Capital Analysts Raise Earnings Estimates for Savara - Defense World
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Savara Inc. (SVRA) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Is Savara Inc. (YB4P) stock supported by free cash flowTreasury Yields & Fast Entry Momentum Trade Alerts - newser.com
What Fibonacci levels say about Savara Inc. rebound2025 Momentum Check & Fast Moving Stock Watchlists - newser.com
Is Savara Inc. stock attractive for income investorsGap Down & Free Long-Term Investment Growth Plans - newser.com
2025-11-16 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Savara Inc. (SVRA) and Encourages Stockholders to Learn More About the Investigation | NDAQ:SVRA | Press Release - Stockhouse
Savara Stock: A High-Risk Opportunity (NASDAQ:SVRA) - Seeking Alpha
Why Savara Inc. stock could outperform in 2025Market Movement Recap & Free Technical Pattern Based Buy Signals - newser.com
Savara (NASDAQ:SVRA) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Volatility clustering patterns for Savara Inc.Trend Reversal & Daily Volume Surge Signals - newser.com
Savara (NASDAQ:SVRA) Stock Price Expected to Rise, Oppenheimer Analyst Says - MarketBeat
Oppenheimer Raises Price Target for Savara (SVRA) to $9.00 | SVR - GuruFocus
Citizens Jmp Cuts Savara (NASDAQ:SVRA) Price Target to $10.00 - MarketBeat
Pattern recognition hints at Savara Inc. upsideQuarterly Portfolio Report & Long-Term Growth Portfolio Plans - newser.com
Oppenheimer Adjusts Price Target on Savara to $9 From $8, Maintains Outperform Rating - MarketScreener
Evaluating Savara Inc. with trendline analysisWeekly Trend Summary & AI Driven Price Predictions - newser.com
Assessing Savara (SVRA) Valuation Following Recent Share Price Momentum - Yahoo Finance
Is Savara Inc. (YB4P) stock in buy zone after pullbackJuly 2025 Retail & Fast Entry High Yield Tips - newser.com
Savara (NASDAQ:SVRA) Posts Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat
Savara Banks Cash As Analysts Stay Upbeat On New Drug - Finimize
Citizens Lowers Price Target for Savara (SVRA) but Maintains Rat - GuruFocus
Citizens lowers Savara stock price target to $10 on dilution concerns - Investing.com Nigeria
Savara Inc Stock (SVRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Savara Inc Stock (SVRA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hawkins Richard J | Director |
Jun 20 '25 |
Buy |
2.04 |
48,225 |
98,572 |
115,466 |
| McCracken Joseph S | Director |
May 29 '25 |
Buy |
2.08 |
10,000 |
20,825 |
260,837 |
| RAMSAY DAVID A | Director |
Mar 31 '25 |
Buy |
2.77 |
150,000 |
416,250 |
2,513,642 |
| Lowrance David L | Chief Financial Officer |
Dec 16 '24 |
Sale |
3.33 |
25,000 |
83,278 |
381,005 |
| Pauls Matthew | CHIEF EXECUTIVE OFFICER |
Dec 16 '24 |
Sale |
3.31 |
54,702 |
180,828 |
1,536,379 |
| Hawkins Richard J | Director |
Dec 16 '24 |
Sale |
3.32 |
8,000 |
26,569 |
67,241 |
0.03%
0.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):